SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
DATE OF REPORT - JUNE 28, 2002
(Date of earliest event reported)
ALKERMES, INC.
(Exact name of Registrant as specified in its charter)
PENNSYLVANIA 0-19267 23-2472830
(State of incorporation) (Commission file number) (IRS employer
identification
number)
64 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)
AREA CODE (617) 494-0171
(Telephone number)
ITEM 5. OTHER INFORMATION.
On June 28, 2002, Johnson & Johnson Pharmaceutical Research &
Development, LLC, ("J&J PRD"), an affiliate of Janssen Pharmaceutica, Inc., a
collaborative partner of Alkermes, Inc., a Pennsylvania corporation
("Alkermes"), received a non-approvable letter from the U.S. Food and Drug
Administration (the "FDA") related to the New Drug Application for Risperdal
Consta(TM), a long-acting formulation of Risperdal(R) utilizing Alkermes'
Medisorb(R) technology.
A copy of the press release issued by Alkermes on July 1, 2002, is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 Press Release issued by Alkermes, Inc., dated July 1,
2002.
2
SIGNATURES
Pursuant to requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: July 1, 2002 Alkermes, Inc.
By: /s/ James M. Frates
----------------------------
James M. Frates
Vice President, Chief Financial
Officer, and Treasurer
3
ALKERMES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Exhibit
----------- -------
99.1 Press Release issued by Alkermes, Inc., dated July 1, 2002.
4